Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

NCT04284774 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04284774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04284774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 13, 2020
Completion date
September 30, 2027
Enrollment
5 (actual)
Sites
172

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid neoplasm, recurrent adrenal gland pheochromocytoma, recurrent ectomesenchymoma, recurrent ependymoma, recurrent ewing sarcoma, recurrent hepatoblastoma, recurrent kidney wilms tumor, recurrent langerhans cell histiocytosis, recurrent malignant germ cell tumor, recurrent malignant glioma, recurrent medulloblastoma, recurrent melanoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent rhabdoid tumor, recurrent rhabdoid tumor of the kidney, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, recurrent thyroid gland carcinoma, recurrent who grade 2 glioma, refractory adrenal gland pheochromocytoma, refractory ependymoma, refractory ewing sarcoma, refractory hepatoblastoma, refractory langerhans cell histiocytosis, refractory malignant germ cell tumor, refractory malignant glioma, refractory medulloblastoma, refractory melanoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory peripheral primitive neuroectodermal tumor, refractory rhabdoid tumor, refractory rhabdoid tumor of the kidney, refractory rhabdomyosarcoma, refractory soft tissue sarcoma, refractory thyroid gland carcinoma, refractory who grade 2 glioma